Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERX-315 in Advanced Solid Tumors
NCT06533332Phase 1Recruiting
- Sponsor
- Etira
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ERX-315 in solid tumor, breast cancer, ovarian cancer and 3 more, sponsored by Etira. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Adverse Events at 12 weeks and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
ERX-315
03
Conditions
solid tumorbreast cancerovarian cancerendometrial cancer (EC)liver cancer
Beyond the preview
Go deeper on NCT06533332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533332.